Joseph Pizzolato is an Oncology physician affiliated with Sylvester Comprehensive Cancer Center. OpenAlex indexes 16 publications with 509 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1475 NW 12th Ave Ste 2and3
Miami, FL 331361002
Telephone
305-243-5302Registry record last updated 31 Oct 2019.
Clinical trials
- Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
Sponsor: Mt. Sinai Medical Center, Miami
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
27 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Caris MPI, Inc.Program year20252 payments
- PFIZER INC.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
36%Corticosteroid15.9%Prednisone100%Part D≥35 patientsSerotonin-3 Receptor Antagonist7%Ondansetron Odt60%Ondansetron Hcl40%Part D<11 patients+ 4 more classes in this area
Cancer & immunology
29.7%Cytochrome P450 17A1 Inhibitor15.3%Abiraterone Acetate100%Part D≥18 patientsKinase inhibitor4.3%Jakafi68%Everolimus32%Part D<11 patients+ 4 more classes in this area
Nervous system
15.6%Opioid Agonist6.4%Oxycodone-Acetaminophen76%Tramadol Hcl24%Part D<11 patientsGabapentinoids2.8%Gabapentin100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effects of aromatherapy inhalation on chemotherapy-induced nausea and vomiting: A controlled trial
European Journal of Oncology Nursing
2026 - Genome-wide host methylation profiling of anal and cervical carcinoma
DOAJ (DOAJ: Directory of Open Access Journals)
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Mikkael Sekeres, MD, MSc
Sylvester Comprehensive Cancer Center
Jonathan Cohen, MD
Sylvester Comprehensive Cancer Center
Chinmay Jani, MD
Sylvester Comprehensive Cancer Center
Jay Spiegel, MD
Sylvester Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”